BIOTECH CATALYST AI SCANNER — July WK2

This issue skews toward hard regulatory dates and, unusually, toward big pharma. Eight of the seventeen names carry a PDUFA or generic-drug action date, clustered between July 11 and August 17 — Celcuity, Capricor, Outlook, MannKind, NRx, Moderna, Merck, and Astellas all have the FDA calendar circled. That's a lot of binary regulatory risk landing in a five-week window, which compresses the usual mix of early data and conference readouts into a smaller share of the list.

The other thing worth flagging up front: this week's forward window happened to pull in several mega-caps — Merck, Moderna, Biogen, Ionis, and argenx all sit alongside the usual micro- and small-cap names. Read their BSI scores for what they measure — catalyst and data quality — not as a proxy for survival risk the way you'd read a $10M company's score. A "Cash Crunch" flag means something very different for a $32B commercial-stage biotech than it does for a company with two months of runway; we've kept the cash-pressure callouts below limited to names where that risk is actually real.

Two of this week's catalysts also appear twice under different tickers — Merck and Astellas both carry the same KEYTRUDA-plus-Padcev bladder cancer decision (they're genuine co-development partners on EV-304), and Biogen and Ionis both carry the same diranersen Alzheimer's readout (Ionis discovered the drug, Biogen co-develops it as BIIB080). Treat those as one catalyst viewed from two balance sheets, not two independent opportunities.

What We're Tracking:

Trading Below Cash: None flagged this week
Cash Pressure: CVKD, MCRB, OTLK
Initial Data: ARGX
Multi-Catalyst: COAG

FEATURED

#1. CVKD — Cadrenal Therapeutics Inc.

THE CATALYST
Event: CAD-1005 (formerly VLX-1005) — Phase 2 Conference Presentation in Heparin-Induced Thrombocytopenia (HIT)
Date: Jul 12, 2026
FDA Status: FTD, ODD
BSI: 8.3/10

Cadrenal picked up the 12-LOX inhibitor portfolio, including CAD-1005, from Veralox Therapeutics in December 2025 — and within months turned an FDA End-of-Phase-2 meeting into direct clearance for pivotal Phase 3, an unusually fast alignment for a company this size. The Ponte Vedra, Florida-based firm focuses on thrombotic and immune conditions, and also carries two earlier-stage assets, tecarfarin (an oral anticoagulant) and frunexian (a Factor XIa inhibitor), neither of which factors into this catalyst.

📈 The Setup: Heparin-induced thrombocytopenia is an immune reaction where heparin exposure triggers platelet activation and dangerous clotting; today's standard of care — direct thrombin inhibitors like argatroban and bivalirudin — controls the clotting cascade but does nothing for the underlying immune trigger. CAD-1005 is a first-in-class, selective small-molecule 12-lipoxygenase (12-LOX) inhibitor (12-LOX is an enzyme that generates pro-thrombotic, pro-inflammatory lipid signals in platelets and immune cells), aiming at that immune root cause directly. In the first-ever randomized, placebo-controlled Phase 2 trial run in HIT, adding CAD-1005 to standard anticoagulation cut new or worsening thrombotic events by more than 25% in absolute terms — even though it missed the original platelet-recovery endpoint. The July 12 ISTH oral presentation delivers that dataset in full, following FDA feedback that it's sufficient to skip straight to a single pivotal Phase 3. No other 12-LOX inhibitor, or any immune-targeted HIT therapy, is in active development.

✅ The Edge: No other therapy in development, or approved, addresses the immune driver behind HIT — CAD-1005 stands alone in that mechanism. It also carries both Fast Track and Orphan Drug designations, and the FDA already agreed to a single pivotal trial rather than requiring a second confirmatory study.

⚠️ The Risk: The efficacy signal comes from one small Phase 2 run by the prior sponsor, not Cadrenal itself, and it missed the platelet-recovery endpoint the trial was originally designed around. With under 8 months of runway, a global Phase 3 in a rare, acute hospital population still needs to be funded almost entirely from scratch.

#2. MRNA — Moderna Inc.

THE CATALYST
Event: mRNA-1010 (P304) — PDUFA Regulatory Decision in seasonal influenza, adults 50+
Date: Aug 05, 2026
BSI: 7.3/10

Moderna's flu program stumbled out of the gate — the FDA issued a Refusal to File on the mRNA-1010 BLA in February — but a Type A meeting reversed course, and a 9-0 Advisory Committee vote in June cleared the way for the current review. The Cambridge, Massachusetts-based company builds its pipeline around mRNA vaccines for respiratory disease, with Blackstone Life Sciences funding up to $750 million of the influenza program specifically.

📈 The Setup: The seasonal flu vaccine market is entrenched — Sanofi's high-dose Fluzone HD and adjuvanted Fluad, plus GSK's standard-dose Fluarix, compete on reactogenicity and physician habit more than on data. mRNA-1010 encodes hemagglutinin (HA, the surface protein flu vaccines train the immune system to recognize) matching the WHO-recommended strains, and it's the only mRNA flu candidate to reach BLA review. In the pivotal P304 trial (roughly 40,800 adults 50 and older), it delivered 26.6% relative efficacy against a licensed standard-dose comparator for confirmed influenza-like illness — enough to drive a unanimous 9-0 Advisory Committee vote, reversing the same comparator concern that triggered February's Refusal to File. Momentum is already running hot into the August 5 decision (RSI 86), so approval is largely priced in; the real question is what label restrictions, if any, apply to the 65-and-older cohort.

✅ The Edge: It's the only mRNA flu vaccine at BLA stage, and the unanimous AdCom vote — after an initial FDA rejection on trial design — signals the data cleared a real bar, not just a formality. Moderna's existing mRNA manufacturing scale also outpaces any rival mRNA flu program still years from filing.

⚠️ The Risk: Approval for the 65-plus cohort would likely lean on an accelerated pathway requiring a post-marketing confirmatory study, given the same comparator debate that caused the earlier Refusal to File. Decades of physician habit sit behind Fluzone HD and Fluad — unseating that on efficacy alone, with RSI already at 86, leaves little room for a soft launch to disappoint the market.

#3. FDMT — 4D Molecular Therapeutics Inc.

THE CATALYST
Event: 4D-150 — Phase 2b Conference Presentation in Wet age-related macular degeneration (AMD)
Date: Jul 18, 2026
FDA Status: RMAT
BSI: 7.2/10

4D Molecular licensed 4D-150's Asia-Pacific rights to Otsuka Pharmaceutical in October 2025, and has since completed enrollment in both global Phase 3 trials ahead of schedule — with topline data not due until 2027, this July readout is an interim look rather than the pivotal event. The Emeryville, California company is focused on genetic medicines for large-market retinal disease and recently added commercial-stage retina expertise to its board.

📈 The Setup: Wet AMD treatment today means repeated intravitreal injections of aflibercept (Eylea) or faricimab (Vabysmo) — effective, but a real burden on patients who need them every one to three months for years. 4D-150 is a single-injection AAV gene therapy (a modified virus used to deliver genetic instructions directly into retinal cells) that expresses both an anti-VEGF antibody fragment and a second anti-VEGF-C transgene, aiming for years of expression from one dose. In the Phase 2b PRISM extension cohort, 52-week data already showed an 83% reduction in supplemental injections versus a projected on-label aflibercept schedule, with more than half of patients injection-free and vision maintained. The July 18 ASRS presentation extends that look to two years — the durability window that matters most for a one-and-done gene therapy pitch. Rival AAV programs, including Adverum's ixo-vec, remain earlier-stage; 4D-150 has already completed Phase 3 enrollment.

✅ The Edge: 4D-150's 83% cut in supplemental injections and majority injection-free rate at 52 weeks is a durability signal no anti-VEGF drug can match regardless of dosing schedule — and it's the furthest along of any AAV gene therapy in wet AMD, with Phase 3 already fully enrolled.

⚠️ The Risk: Prior-generation gene therapies in this class have seen durability fade past 18 months in some patients, and this cohort is only now reaching two years. Retinal gene therapy also carries a class-wide inflammation risk regulators watch closely — any uptick at the Phase 3 dose would complicate the story RMAT designation is meant to accelerate.

#4. CELC — Celcuity Inc.

THE CATALYST
Event: Gedatolisib with Fulvestrant (VIKTORIA-1) — PDUFA Regulatory Decision in HR+/HER2- advanced breast cancer
Date: Jul 17, 2026
FDA Status: BTD, FTD
BSI: 7.1/10

Celcuity priced an upsized convertible note offering in June, the kind of pre-launch balance-sheet move a company makes when it expects to be commercial soon. The Minneapolis-based oncology developer has no disclosed co-development partner for gedatolisib — this is a solo bet — and the FDA accepted the NDA with Priority Review in January, setting up the current decision.

📈 The Setup: For HR+/HER2- breast cancer patients who progress after a CDK4/6 inhibitor and endocrine therapy, the only approved PI3K-pathway option is alpelisib (Piqray) — and it only works if the tumor carries a PIK3CA mutation, leaving everyone else with chemotherapy or everolimus. Gedatolisib is a pan-PI3K/mTOR inhibitor (it blocks all four class I PI3K isoforms plus both mTOR complexes, rather than a single node other drugs hit) built to work regardless of mutation status. In Phase 3 VIKTORIA-1's PIK3CA wild-type cohort, both the gedatolisib-fulvestrant doublet and the triplet with palbociclib produced statistically significant, clinically meaningful progression-free survival gains over fulvestrant alone — and in the separate mutant cohort, the regimens roughly doubled the odds of progression-free survival versus alpelisib-fulvestrant. With Priority Review already in hand and topline data already positive, July 17 reads as closer to a formality than a coin flip — the market has largely priced in approval.

✅ The Edge: Gedatolisib is the first PAM-pathway inhibitor to post positive Phase 3 results specifically in the PIK3CA wild-type population — the majority of HR+/HER2- patients, who currently have no PI3K-pathway option at all. Priority Review plus Breakthrough and Fast Track designations reflect real regulatory conviction, not just sponsor optimism.

⚠️ The Risk: This is an IV regimen launching into a market built around oral pills, and the strongest efficacy numbers come from the three-drug combination, which layers on palbociclib's neutropenia. The company is still pre-revenue and has to build commercial infrastructure and specialty-pharmacy contracts from scratch inside a narrow post-approval window.

#5. MCRB — Seres Therapeutics Inc.

THE CATALYST
Event: SER-155 — Phase 2 Conference Presentation in Allogeneic Hematopoietic Stem Cell Transplantation
Date: Mid-2026 (Est.)
FDA Status: BTD, FTD
BSI: 7.0/10

Seres sold VOWST, its first approved microbiome drug, to Nestlé Health Science in 2024, and a June 2026 milestone payment extended the runway a little further — but the company paused further investment in SER-155's pivotal Phase 2 back in February while it hunts for capital or a partner. The Cambridge, Massachusetts-based company builds live bacterial therapeutics, leaning on a long-standing Memorial Sloan Kettering collaboration for its clinical work.

📈 The Setup: There's no approved microbiome therapy for preventing bloodstream infections after a stem-cell transplant — the standard is broad-spectrum antibiotic prophylaxis, which drives resistance over time. SER-155 is an oral live biotherapeutic (a cultivated consortium of 16 bacterial strains) designed to crowd out gut pathogens and shore up the intestinal barrier that antibiotics and transplant conditioning damage. In the randomized Phase 1b, bloodstream infections fell to 10% versus 43% on placebo, and antibiotic treatment days dropped by more than half — a large effect that helped earn Breakthrough and Fast Track status. The July data are from a related but different setting: an investigator-sponsored trial in checkpoint-inhibitor colitis, not the paused allo-HSCT Phase 2 itself. Read it as a test of whether the same mechanism generalizes to a second immunocompromised population, not as a pivotal allo-HSCT result — the actual pivotal trial remains unfunded.

✅ The Edge: The Phase 1b bloodstream-infection reduction (10% versus 43% on placebo) is a large, statistically significant effect in a setting where no microbiome competitor exists — Vedanta's VE303 targets a different indication (C. difficile) entirely.

⚠️ The Risk: The pivotal allo-HSCT Phase 2 is paused for lack of funding, and even a clean read from the unrelated colitis trial doesn't restart it without fresh capital or a partner. With roughly 2 months of runway against a $75M cap, that financing need is immediate and likely dilutive.

#6. CAPR — Capricor Therapeutics Inc.

THE CATALYST
Event: Deramiocel (CAP-1002) (HOPE-2) — FDA Ad Com (Advisory Committee) in Duchenne Muscular Dystrophy (DMD)
Date: Jul 29, 2026
FDA Status: ODD
BSI: 6.9/10

Capricor's commercial partner, Nippon Shinyaku (NS Pharma), holds exclusive US and Japan rights to deramiocel under an existing agreement — and the FDA lifted a prior Complete Response Letter in March after the company submitted fresh HOPE-3 Phase 3 data. The San Diego-based company focuses on cell and exosome therapeutics for rare disease, with Duchenne cardiomyopathy as its lead program.

📈 The Setup: Sarepta's Elevidys gene therapy and several exon-skipping drugs already treat Duchenne muscular dystrophy, but most of that arsenal targets skeletal muscle and either requires a specific mutation or a viral vector — the cardiomyopathy that ultimately kills DMD patients is still largely unaddressed. Deramiocel is an allogeneic cardiosphere-derived cell therapy (CDCs, a population of cardiac stromal cells with immune-modulating and anti-fibrotic effects) that's mutation-agnostic and aimed squarely at that cardiac and skeletal decline. Phase 3 HOPE-3 (n=106) hit its primary endpoint with a 54% slowing of upper-limb function decline and a key secondary cardiac endpoint (91% slowing of ejection-fraction decline), while five-year HOPE-2 extension data show that benefit holding up over time. An Ad Com on July 29 precedes the August PDUFA — a genuinely pivotal event, but one following a prior CRL, so the question is whether the FDA now considers the evidence sufficient.

✅ The Edge: Deramiocel would be the only mutation-agnostic cell therapy approved for DMD cardiomyopathy specifically — a gap Elevidys and the exon-skipping drugs don't close — backed by five years of durability data most competitors in the space can't show.

⚠️ The Risk: The prior CRL cited insufficient evidence of effectiveness, and the Ad Com will weigh that same question against a single Phase 3 trial plus an open-label extension rather than two independent pivotal studies. Manufacturing and quarterly IV-infusion logistics for a cell therapy in pediatric patients also remain largely untested at commercial scale.

#7. OTLK — Outlook Therapeutics Inc.

THE CATALYST
Event: LYTENAVA (bevacizumab-vikg) / ONS-5010 (NORSE EIGHT) — PDUFA Regulatory Decision in Wet age-related macular degeneration (wet AMD)
Date: Jul 29, 2026
FDA Status: BTD
BSI: 6.9/10

Outlook already sells LYTENAVA in the EU and UK, including Germany, as the first authorized ophthalmic bevacizumab for wet AMD — but the US path has been rockier, with multiple prior Complete Response Letters. A Formal Dispute Resolution appeal earlier this year got the FDA to affirm substantial evidence of effectiveness, clearing the way for the current Class 1 resubmission. The Iselin, New Jersey company leaned on a $5 million registered direct offering from major shareholder GMS Ventures in May to help bridge to this decision.

📈 The Setup: Off-label compounded Avastin is the actual volume leader in wet AMD today, used widely because it's cheap — branded anti-VEGF drugs like Lucentis, Eylea, and Vabysmo cost far more for a similar mechanism. LYTENAVA is that same molecule, bevacizumab (an antibody that blocks VEGF, the protein driving the leaky blood vessels behind vision loss), but manufactured and formulated specifically for the eye under FDA oversight rather than compounded ad hoc. NORSE TWO already showed it beating ranibizumab on vision gains, and NORSE EIGHT reached non-inferiority to ranibizumab on visual acuity at week 12 after missing its earlier week-8 primary endpoint. The dispute-resolution win means the FDA now accepts that combined package as adequate. If cleared, LYTENAVA becomes the only FDA-approved on-label alternative to compounded Avastin — but the stock has already run up nearly 80% into the date, and cash on hand covers well under four months.

✅ The Edge: LYTENAVA would be the only FDA-approved ophthalmic bevacizumab on the market — a regulated, manufactured alternative sitting between cheap compounded Avastin and the far pricier branded anti-VEGF drugs, with 12 years of exclusivity attached to a first approval.

⚠️ The Risk: Multiple prior CRLs, including manufacturing findings, leave real room for another information request even under Class 1 review, and post-approval scale-up of US manufacturing is unproven. With under four months of cash, any delay forces financing at a moment of maximum leverage for whoever's on the other side of the table.

#8. ARGX — argenx SE

THE CATALYST
Event: Empasiprubart (VARVARA) — Phase 2 Topline Data in Delayed graft function (DGF)
Date: Mid-2026 (Est.)
BSI: 6.5/10

argenx runs a global immunology franchise anchored by VYVGART (efgartigimod), which funds it to take shots on earlier-stage bets like this one — a strategy underscored by a 2026 licensing deal with Tensegrity that carries an acquisition option, and a new China affiliate opened in March to access novel biology. The Amsterdam-domiciled company trades as an ADR on Nasdaq alongside its Euronext Brussels listing.

📈 The Setup: Delayed graft function — a transplanted kidney's early failure to work — has no approved disease-modifying therapy; management today means induction immunosuppression and dialysis until the organ recovers or doesn't. Empasiprubart is a long-acting "sweeping" antibody (engineered to recycle via the neonatal Fc receptor and clear its target repeatedly rather than being used up) that blocks complement protein C2, shutting down the classical and lectin immune pathways that drive ischemia-reperfusion injury while leaving the alternative pathway intact. The Phase 2 VARVARA trial dosed deceased-donor kidney recipients around transplant on top of standard care, with a 52-week kidney-function readout as the primary endpoint — a longer window than the usual early dialysis-avoidance measure, testing whether the effect actually holds. Only Phase 1 safety and target-engagement data exist so far; this mid-2026 readout is the first efficacy look in the indication. No other complement inhibitor, including past attempts with eculizumab, has succeeded here.

✅ The Edge: Empasiprubart is the only C2-targeted complement blocker in transplant development, and the 52-week endpoint gives a durability read most DGF studies don't bother collecting — backed by a company with the balance sheet to fund a full Phase 3 regardless of how this readout lands.

⚠️ The Risk: This is the first efficacy data ever generated for this mechanism in this indication — there's no precedent to lean on, and prior complement inhibitors like eculizumab have failed to translate promising biology into transplant outcomes. The FDA has little history evaluating DGF endpoints, so even a positive signal may draw questions about what's actually "clinically meaningful."

#9. MNKD — MannKind Corporation

THE CATALYST
Event: FUROSCIX ReadyFlow Autoinjector (SCP-111) — PDUFA Regulatory Decision in Edema in adult patients with CHF or CKD
Date: Jul 26, 2026
BSI: 6.3/10

MannKind acquired scPharmaceuticals in late 2025, picking up the existing FUROSCIX On-body Infusor franchise along with it — the December 2025 pediatric approval and a record Q4 revenue quarter show that base business already working. The Danbury, Connecticut company also runs an active collaboration with United Therapeutics on inhaled dry-powder products built on its Technosphere platform.

📈 The Setup: The already-approved FUROSCIX On-body Infusor delivers subcutaneous furosemide (a loop diuretic that flushes excess fluid by blocking sodium reabsorption in the kidney) over five hours, letting heart-failure and kidney-disease patients dose at home instead of an IV clinic visit. SCP-111 is the same drug in a new ReadyFlow autoinjector format, compressing that five-hour infusion to under 10 seconds. A Phase 1 crossover study in older adults showed pharmacokinetics and pharmacodynamics comparable to IV furosemide — similar urine output and sodium excretion — which is the bridge the FDA is reviewing rather than a fresh efficacy trial. No other subcutaneous furosemide autoinjector exists; the alternative is still IV administration or oral loop diuretics. This is device engineering layered onto an already-proven drug and an already-approved delivery mechanism, not a new molecular bet.

✅ The Edge: No competing subcutaneous furosemide autoinjector exists, and MannKind already has a commercial diuretic franchise and sales channel in place from the scPharmaceuticals deal — a faster path to shelf space than a company launching cold.

⚠️ The Risk: The clinical package behind SCP-111 is a single Phase 1 PK/PD bridging study in healthy older adults, not an outcomes trial — the FDA could still ask for additional human-factors or usability data on the novel autoinjector format before signing off, even with the underlying drug already established.

#10. MLTX — MoonLake Immunotherapeutics

THE CATALYST
Event: Nanobody sonelokimab (IZAR-1) — Phase 3 Initial Data in Active psoriatic arthritis (PsA)
Date: Mid-2026 (Est.)
BSI: 6.2/10

MoonLake is still working back from a September 2025 selloff, when mixed Phase 3 VELA data in hidradenitis suppurativa cut the stock more than 80%. Since then, a positive pre-BLA meeting with the FDA on the HS program and a proposed $150 million raise in June suggest the company sees that path as still viable. The Zug, Switzerland-based, Nasdaq-listed company licensed sonelokimab from Merck KGaA/EMD Serono and Avillion.

📈 The Setup: Psoriatic arthritis already has multiple approved IL-17A biologics — secukinumab, ixekizumab — plus bimekizumab, which blocks both IL-17A and IL-17F. Sonelokimab is a Nanobody (a small, single-domain antibody fragment, more compact than a conventional antibody) that also dual-targets IL-17A and IL-17F, aiming to match or beat bimekizumab's dual-blockade approach in a smaller, more tissue-penetrant format. In the earlier Phase 2 ARGO trial, the 60mg dose produced ACR50 response rates above 60% and PASI90 skin-clearance rates above 67% in biologic-naïve patients at week 24 — numbers that beat the adalimumab comparator arm in the same trial. IZAR-1 is testing whether that holds up against placebo at week 16 in a larger, radiographic-endpoint Phase 3. This is the redemption angle: after VELA's miss in a different indication, a clean PsA readout would decouple the sonelokimab story from that failure and put weight back behind the HS resubmission.

✅ The Edge: The Phase 2 ARGO data already numerically beat the adalimumab comparator arm on ACR50 and skin clearance — a dual IL-17A/F Nanobody format that, if IZAR-1 confirms it, would put sonelokimab ahead of same-class biologics on response depth, not just mechanism novelty.

⚠️ The Risk: VELA's Phase 3 miss in hidradenitis suppurativa is the shadow over this readout — a live reminder that MoonLake's Phase 2 signals haven't always held at Phase 3 scale. IZAR-1 needs to separate cleanly from placebo on ACR50 at week 16; a repeat of the VELA pattern would remove the company's last near-term catalyst.

WATCHLIST

#11. MRK — Merck & Company Inc. [Oncology]

Price: $129.56 | Cap: $319.99B | Cash: $9.79B | RSI: 66 | Momentum: +13.0%
KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin) — PDUFA Regulatory Decision in Muscle-invasive bladder cancer (KEYNOTE-B15/EV-304) (Aug 17, 2026)
BSI: 6.0/10

The Intel: Merck's Keytruda (a PD-1 checkpoint inhibitor that reactivates T-cell attacks on tumors) paired with Astellas/Pfizer's Padcev (an antibody-drug conjugate targeting Nectin-4 to deliver chemotherapy directly to tumor cells) is under review for use before and after bladder-removal surgery — the first ADC-immunotherapy combination filed for this perioperative setting. EV-304's topline showed the combination cutting recurrence risk versus chemotherapy alone. The regulatory case looks solid; the swing factor is whether payers and surgeons adopt a costlier combination regimen over established chemo ahead of an operation most patients want done quickly.

#12. NRXP — NRx Pharmaceuticals Inc. [CNS]

Price: $3.87 | Cap: $140.2M | Cash: $24.5M | RSI: 48 | Momentum: -4.4%
KETAFREE — GDUFA Regulatory Decision on Preservative-free intravenous ketamine formulation (Jul 29, 2026)
BSI: 5.9/10

The Intel: KETAFREE isn't a new molecule — it's an abbreviated filing seeking approval for a single-patient, preservative-free vial of IV ketamine (an NMDA-receptor blocker already used in anesthesia and depression care), differentiated mainly by removing benzethonium chloride, a preservative the FDA doesn't classify as safe for repeated dosing. The FDA's Office of Generic Drugs already flagged no bioequivalence deficiencies in March, which meaningfully de-risks the regulatory path. The open question is commercial: hospital formularies default to the cheapest multi-dose generic already on the shelf, and nothing here forces a switch.

The Strategist's Take

The calendar is doing most of the work this week. Eight of seventeen names carry a hard PDUFA or generic-action date between July 11 and August 17 — Celcuity, Capricor, Outlook, MannKind, NRx, Moderna, and the shared Merck/Astellas bladder-cancer filing all land inside a five-week window. That's an unusually dense stretch of binary regulatory risk, and it's why this issue reads as decision-heavy rather than data-heavy.

The top of the featured list is genuinely strong. Cadrenal (8.3) leads on the strength of a rare, disease-modifying mechanism with FDA already committed to a single pivotal trial — about as clean a small-cap binary as this scanner finds, if the balance sheet can hold together. Moderna (7.3), 4D Molecular (7.2), and Celcuity (7.1) round out a tier where the data is already largely in hand and the remaining catalyst is closer to confirmation than discovery. Worth calling out explicitly: this issue's big-cap names — Moderna, Merck, Astellas, Biogen, Ionis, argenx — score on catalyst and data quality the same way the micro-caps do, but their cash and runway figures don't carry the same meaning. A "Cash Crunch" tag means something different for a company with Merck's balance sheet than it does for Cadrenal's; we've written the risk sections accordingly rather than treating every name's financing picture as equally urgent.

Two pairs deserve a specific note. Merck (6.0) and Astellas (5.8) are the same EV-304 bladder-cancer decision from two sides of the same partnership — don't treat them as diversification. Same story with Biogen (4.9) and Ionis (4.5) on diranersen: one drug, one trial, one outcome, split across two tickers with different balance-sheet stakes. And on the cash-pressured side, the real story is the micro-cap trio — Cadrenal, Seres (7.0), and Outlook (6.9) — where genuinely strong data sits next to single-digit months of runway. Strong science doesn't fund itself; size those three with that in mind.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.3 | Generated: 2026-07-03T17:20:35